Company intelligence / Profile preview
Biotech Equity Partners
- Ownership
- Private
- Development stage
- Other
01
Overview
The primary objective of the Phase I study was to determine safety and tolerability of FP253, a gene-directed enzyme prodrug system designed to localize chemotherapy activation within the prostate. No published results are available; current clinical status is unknown.
- Therapeutic areas
- Oncology
- Modalities
- Gene therapyViral vector-based therapyEnzyme replacement therapy (via gene-directed enzyme prodrug therapy, GDEPT)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Biotech Equity Partners.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biotech Equity Partners.